HRTX Valuation

Heron Therapeutics Inc

Add to Watchlist

Advanced Chart

1.300

+0.07(5.691%)1D

Overview
Forecast
Valuation
Earnings

HRTX Relative Valuation

HRTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HRTX is overvalued; if below, it's undervalued.

Historical Valuation

Heron Therapeutics Inc (HRTX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.35 is considered Fairly compared with the five-year average of -85.63. The fair price of Heron Therapeutics Inc (HRTX) is between 0.68 to 7.22 according to relative valuation methord.

Relative Value

Fair Zone

0.68-7.22

Current Price：1.23

Fair

-1625.00

Trailing

Forward

0.00

EV/EBITDA

Heron Therapeutics Inc. (HRTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.98. The thresholds are as follows: Strongly Undervalued below -17.82, Undervalued between -17.82 and -10.40, Fairly Valued between 4.44 and -10.40, Overvalued between 4.44 and 11.87, and Strongly Overvalued above 11.87. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

47.43

EV/EBIT

Heron Therapeutics Inc. (HRTX) has a current EV/EBIT of 47.43. The 5-year average EV/EBIT is -82.06. The thresholds are as follows: Strongly Undervalued below -1657.96, Undervalued between -1657.96 and -870.01, Fairly Valued between 705.89 and -870.01, Overvalued between 705.89 and 1493.84, and Strongly Overvalued above 1493.84. The current Forward EV/EBIT of 47.43 falls within the Historic Trend Line -Fairly Valued range.

1.35

Heron Therapeutics Inc. (HRTX) has a current PS of 1.35. The 5-year average PS is 4.81. The thresholds are as follows: Strongly Undervalued below -4.18, Undervalued between -4.18 and 0.32, Fairly Valued between 9.31 and 0.32, Overvalued between 9.31 and 13.80, and Strongly Overvalued above 13.80. The current Forward PS of 1.35 falls within the Historic Trend Line -Fairly Valued range.

11.59

P/OCF

Heron Therapeutics Inc. (HRTX) has a current P/OCF of 11.59. The 5-year average P/OCF is -6.20. The thresholds are as follows: Strongly Undervalued below -50.69, Undervalued between -50.69 and -28.44, Fairly Valued between 16.04 and -28.44, Overvalued between 16.04 and 38.28, and Strongly Overvalued above 38.28. The current Forward P/OCF of 11.59 falls within the Historic Trend Line -Fairly Valued range.

5.91

P/FCF

Heron Therapeutics Inc. (HRTX) has a current P/FCF of 5.91. The 5-year average P/FCF is -0.17. The thresholds are as follows: Strongly Undervalued below -33.85, Undervalued between -33.85 and -17.01, Fairly Valued between 16.68 and -17.01, Overvalued between 16.68 and 33.52, and Strongly Overvalued above 33.52. The current Forward P/FCF of 5.91 falls within the Historic Trend Line -Fairly Valued range.

Heron Therapeutics Inc (HRTX) has a current Price-to-Book (P/B) ratio of -6.92. Compared to its 3-year average P/B ratio of -4.77 , the current P/B ratio is approximately 44.93% higher. Relative to its 5-year average P/B ratio of -0.46, the current P/B ratio is about 1396.42% higher. Heron Therapeutics Inc (HRTX) has a Forward Free Cash Flow (FCF) yield of approximately -13.10%. Compared to its 3-year average FCF yield of -31.41%, the current FCF yield is approximately -58.30% lower. Relative to its 5-year average FCF yield of -28.65% , the current FCF yield is about -54.28% lower.

-7.31

P/B

Median3y

-4.77

Median5y

-0.46

-13.10

FCF Yield

Median3y

-31.41

Median5y

-28.65

Competitors Valuation Multiple

The average P/S ratio for HRTX's competitors is 2.13, providing a benchmark for relative valuation. Heron Therapeutics Inc Corp (HRTX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 3.26%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

HRTX.O

Heron Therapeutics Inc

NeOnc Technologies Holdings Inc

Voyager Therapeutics Inc

Performance Decomposition

Market capitalization of HRTX decreased by 34.67% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -123.89 to -169.87.

The secondary factor is the Revenue Growth, contributed 3.26%to the performance.

Overall, the performance of HRTX in the past 1 year is driven by P/E Change. Which is more unsustainable.

3.26%

36.02M → 37.20M

Revenue Growth

-75.04%

-25.64 → -6.40

Margin Expansion

37.11%

-123.89 → -169.87

P/E Change

-34.67%